<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925234</url>
  </required_header>
  <id_info>
    <org_study_id>M15DRU</org_study_id>
    <nct_id>NCT02925234</nct_id>
  </id_info>
  <brief_title>The Drug Rediscovery Protocol (DRUP Trial)</brief_title>
  <acronym>DRUP</acronym>
  <official_title>A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized clinical trial that aims to describe the efficacy and&#xD;
      toxicity of commercially available, targeted anticancer drugs* prescribed for treatment of&#xD;
      patients with advanced cancer with a potentially actionable variant as revealed by a genomic&#xD;
      or protein expression test. The study also aims to simplify patient access to approved&#xD;
      targeted therapies that are contributed to the program by collaborating pharmaceutical&#xD;
      companies and to perform next generation sequencing on tumor biopsies for biomarker analyses.&#xD;
      Eligible patients have an advanced solid tumor, multiple myeloma or B cell non-Hodgkin&#xD;
      lymphoma for which standard treatment options are no longer available and acceptable&#xD;
      performance status and organ function. A genomic or protein expression test must have been&#xD;
      performed on the tumor and the results must identify at least one potentially actionable&#xD;
      molecular variant as defined in the protocol. Results from the molecular profiling test will&#xD;
      be used to determine an appropriate drug(s) from among those available in the protocol. The&#xD;
      choice of drug will be supported by a list of potential profiles, a molecular tumor board, a&#xD;
      knowledge library and by study coordinators for review and approval of the match. The&#xD;
      protocol-specified treatment will be administered to the patient once any drug-specific&#xD;
      eligibility criteria are confirmed and a fresh pre-treatment biopsy is performed for future&#xD;
      genetic studies. All patients who receive treatment with a drug available in the protocol&#xD;
      will be followed for standard efficacy outcomes including tumor response, progression-free&#xD;
      and overall survival as well as duration of treatment. In addition, treatment related&#xD;
      toxicity will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Problem description: evidence is building that matching targeted agents to tumor&#xD;
      characteristics can improve outcomes. Such reports have fueled interest among patients and&#xD;
      physicians to use molecular testing for treatment planning when standard treatment options&#xD;
      have been exhausted. When oncologists aim to provide such personalized treatment to their&#xD;
      patients though, obtaining the drugs can be challenging since off-label prescribing, while&#xD;
      legal, is generally not reimbursed by insurance companies. Furthermore, outcomes of off-label&#xD;
      treatment in routine clinical practice are not systematically recorded. As a result, the&#xD;
      research and clinical communities have limited insight in these outcomes, leading to&#xD;
      repetitive use of ineffective treatment for some tumor types, while effective treatment&#xD;
      strategies might be missed for others. The latter is especially relevant for 'orphan&#xD;
      diseases', that are too rare to conduct formal phase II and III trials. In summary, there is&#xD;
      a lack of access to potentially effective therapy on one hand, and a lack of knowledge on&#xD;
      broader use of such therapies on the other, altogether leading to sub-optimal use of&#xD;
      available resources.&#xD;
&#xD;
      Envisioned solution and study aim: creation of a drug-access program, in which patients are&#xD;
      treated with registered targeted therapy matched to their molecular tumor profile, and in&#xD;
      which the outcomes of such therapies are recorded systematically, per tumor profile and tumor&#xD;
      type (this is important since it is becoming increasingly clear that the tissue of origin is&#xD;
      an important determinant of outcome of genetic abnormalities). We hereby aim to improve and&#xD;
      broaden the use of registered targeted therapy, whilst facilitating patient access to such&#xD;
      therapy.&#xD;
&#xD;
      Plan of investigation: patients will be treated with approved targeted agents, selected based&#xD;
      on results of a molecular profiling test of the patient's tumor. Eligible patients will have&#xD;
      exhausted standard treatment options, and their tumor must harbor a potentially actionable&#xD;
      molecular variant as defined in the protocol. The study will provide a tumor board to help&#xD;
      physicians understand the profiling test results and treatment options, and will enable&#xD;
      insights about the utility of this approach. In addition, next generation sequencing will be&#xD;
      performed on fresh tumor biopsies for additional biomarker discovery. Patients from the&#xD;
      Netherlands and the USA will be included in two similar though independent protocols (DRUP&#xD;
      and TAPUR), allowing data-exchange and empowering of both trials.&#xD;
&#xD;
      Expected outcome: early signs of clinical activity of approved drugs outside their label,&#xD;
      providing effective personalized treatment options, improved patient outcomes and access to&#xD;
      targeted therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients that are treated based on their molecular tumor profile</measure>
    <time_frame>6 months after treatment initiation (estimated average)</time_frame>
    <description>Primary outcome measure 1 is the percentage of submitted patients, that can be treated based on their molecular tumor profile within the context of this protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>6 months after treatment initiation (estimated average)</time_frame>
    <description>Primary outcome measure 2 is the proportion of study participants with an objective tumor response upon study treatment..</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stable disease</measure>
    <time_frame>6 months after treatment initiation (estimated average)</time_frame>
    <description>Primary outcome measure 3 is the proportion of study participants that has stable disease (SD) during study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related gradeâ‰¥3 and serious adverse events</measure>
    <time_frame>6 months after treatment initiation (estimated average)</time_frame>
    <description>Primary outcome measure 4 is the proportion of patients that experience treatment-related gradeâ‰¥3 and /or serious adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 1 year after study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year after study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment on study (time on drug)</measure>
    <time_frame>6 months after treatment initiation (estimated average)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Concordance between pre-treatment and historic mutational tumor profile</measure>
    <time_frame>2 months after treatment initiation (estimated average)</time_frame>
    <description>Sequencing results of fresh pre-treatment biopsies will be available within 2 months after treatment initiation.</description>
  </other_outcome>
  <number_of_arms>33</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Cancer</condition>
  <condition>Tumors</condition>
  <condition>Neoplasm</condition>
  <condition>Neoplasia</condition>
  <arm_group>
    <arm_group_label>Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab for patients with a molecular tumor profile that can potentially be targeted by Panitumumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaparib for patients with a molecular tumor profile that can potentially be targeted by Olaparib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabrafenib for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nilotinib for patients with a molecular tumor profile that can potentially be targeted by nilotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib for patients with a molecular tumor profile that can potentially be targeted by trametinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib for patients with a molecular tumor profile that can potentially be targeted by erlotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab &amp; Pertuzumab (combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab and Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab and Pertuzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vemurafenib &amp; Cobimetinib (combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vemurafenib and Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib and Cobimetinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vismodegib for patients with a molecular tumor profile that can potentially be targeted by vismodegib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib for patients with a molecular tumor profile that can potentially be targeted by regorafenib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab for patients with a molecular tumor profile that can potentially be targeted by nivolumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Afatinib for patients with a molecular tumor profile that can potentially be targeted by Afatinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib &amp; trametinib (combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabrafenib and trametinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib and trametinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib for patients with a molecular tumor profile that can potentially be targeted by Ribociclib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenvatinib for patients with a molecular tumor profile that can potentially be targeted by Lenvatinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab for patients with a molecular tumor profile that can potentially be targeted by Pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab for patients with a molecular tumor profile that can potentially be targeted by Durvalumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rucaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rucaparib for patients with a molecular tumor profile that can potentially be targeted by Rucaparib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib for patients with a molecular tumor profile that can potentially be targeted by Palbociclib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crizotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crizotinib for patients with a molecular tumor profile that can potentially be targeted by Crizotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib for patients with a molecular tumor profile that can potentially be targeted by Sunitinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabozantinib for patients with a molecular tumor profile that can potentially be targeted by Cabozantinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib for patients with a molecular tumor profile that can potentially be targeted by Abemaciclib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alectinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab/bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab and bevacizumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab and bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipilimumab/nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab and nivolumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Ipilimumab and nivolumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entrectinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entrectinib for patients with a molecular tumor profile that can potentially be targeted by entrectinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Talazoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talazoparib for patients with a molecular tumor profile that can potentially be targeted by talazoparib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dacomitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dacomitinib for patients with a molecular tumor profile that can potentially be targeted by dacomitinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorlatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorlatinib for patients with a molecular tumor profile that can potentially be targeted by lorlatinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erdafitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erdafitinib for patients with a molecular tumor profile that can potentially be targeted by erdafitinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpelisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpelisib for patients with a molecular tumor profile that can potentially be targeted by alpelisib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Panitumumab</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Olaparib</arm_group_label>
    <other_name>Lynparza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Dabrafenib</arm_group_label>
    <other_name>Tafinlar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Trametinib</arm_group_label>
    <other_name>Mekinist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab and Pertuzumab (combination treatment)</intervention_name>
    <description>Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Trastuzumab &amp; Pertuzumab (combination)</arm_group_label>
    <other_name>Herceptin + Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib and Cobimetinib (combination treatment)</intervention_name>
    <description>Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Vemurafenib &amp; Cobimetinib (combination)</arm_group_label>
    <other_name>Zelboraf + Cotellic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Vismodegib</arm_group_label>
    <other_name>Erivedge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Regorafenib</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Afatinib</arm_group_label>
    <other_name>Giotrif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib and trametinib</intervention_name>
    <description>Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Dabrafenib &amp; trametinib (combination)</arm_group_label>
    <other_name>Tafinlar and Mekinist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Ribociclib</arm_group_label>
    <other_name>Kisqali</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Lenvatinib</arm_group_label>
    <other_name>Lenvima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Durvalumab</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Rucaparib</arm_group_label>
    <other_name>Rubraca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Axitinib</arm_group_label>
    <other_name>Inlyta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Palbociclib</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Crizotinib</arm_group_label>
    <other_name>Xalkori</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Cabozantinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Abemaciclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Alectinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab and Bevacizumab</intervention_name>
    <description>Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Atezolizumab/bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab and nivolumab</intervention_name>
    <description>Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Ipilimumab/nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Entrectinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Talazoparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacomitinib</intervention_name>
    <description>Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>dacomitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorlatinib</intervention_name>
    <description>Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Lorlatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erdafitinib</intervention_name>
    <description>Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Erdafitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpelisib</intervention_name>
    <description>Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.</description>
    <arm_group_label>Alpelisib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (age &gt;18 years) patient with a histologically-proven locally advanced or&#xD;
             metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no&#xD;
             longer benefitting from standard anti-cancer treatment or for whom no such treatment&#xD;
             is available or indicated.&#xD;
&#xD;
             * For GBM patients: Histologically confirmed recurrent or de novo glioblastoma&#xD;
             (primary), with unequivocal first progression after radiotherapy and&#xD;
             concurrent/adjuvant chemotherapy, at least 3 months after the concomitant part of the&#xD;
             chemo-radiotherapy, and with stable or decreasing dosage of steroids for at least 7&#xD;
             days prior to the baseline MRI scan.&#xD;
&#xD;
          2. ECOG performance status 0-2&#xD;
&#xD;
          3. Patients must have acceptable organ function as defined below. However, specific&#xD;
             inclusion/exclusion criteria specified in the drug-specific study manual will take&#xD;
             precedence:&#xD;
&#xD;
               1. Absolute neutrophil count â‰¥ 1.5 x 109/l&#xD;
&#xD;
               2. Hemoglobin &gt; 5.6 mmol/l&#xD;
&#xD;
               3. Platelets &gt; 75 x 109/l&#xD;
&#xD;
               4. Total bilirubin &lt; 2 x ULN&#xD;
&#xD;
               5. AST (SGOT) and ALT (SGPT) &lt; 2.5 x institutional ULN (or &lt; 5 x ULN in patients&#xD;
                  with known hepatic metastases)&#xD;
&#xD;
               6. Serum creatinine â‰¤ 1.5 Ã— ULN or calculated or measured creatinine clearance â‰¥ 50&#xD;
                  mL/min/1.73 m2&#xD;
&#xD;
          4. Patients must have objectively evaluable or measurable disease (by physical or&#xD;
             radiographic examination, according to RECIST v1.1 for patients with solid tumors, or&#xD;
             according to IMWG, Lugano, RANO or GCIG criteria, resp., for patients with multiple&#xD;
             myeloma, non-Hodgkin lymphoma, glioblastoma or ovarian cancer in case of CA125-based&#xD;
             evaluation (please refer to appendices for further details) [16, 17].&#xD;
&#xD;
          5. Results must be available from a tumor genomic or protein expression test. Eligible&#xD;
             tests may include any of the following technologies: fluorescence in situ&#xD;
             hybridization (FISH), polymerase chain reaction (PCR), comparative genomic&#xD;
             hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC).&#xD;
             The test may have been performed on the primary tumor or a metastatic deposit, in a&#xD;
             diagnostic laboratory or within the context of another CPCT study, and must reveal a&#xD;
             potentially actionable variant as defined in Section 5. The test results (full&#xD;
             pathology or molecular diagnostics report) must be uploaded in the eCRF.&#xD;
&#xD;
          6. Patients must have a tumor profile for which single agent treatment with one of the&#xD;
             EMA approved targeted anti-cancer drugs included in this study has potential clinical&#xD;
             benefit based on preclinical data or clinical information (see section 5).&#xD;
&#xD;
          7. A new (obtained â‰¤2 months before inclusion, and without any type of anti-cancer&#xD;
             therapy within those â‰¤2 months ) fresh frozen tumor biopsy specimen for extensive&#xD;
             biomarker testing is mandatory before the start of treatment with a targeted agent&#xD;
             included in the protocol.&#xD;
&#xD;
             *For GBM patients:&#xD;
&#xD;
             The mandatory fresh frozen tumor biopsy sample can be obtained through&#xD;
             standard-of-care surgical procedures (i.e., performed at progression, for&#xD;
             cytoreduction, to proof progressive disease, or to reduce mass effect on the&#xD;
             surrounding brain tissue). Thus, surgical procedures are standard-of-care and not part&#xD;
             of trial participation. Fresh frozen tumor tissue must have been obtained â‰¤2 months&#xD;
             before inclusion, and without any type of anti-cancer therapy within those â‰¤2 months.&#xD;
             After surgical procedures, patients must meet the following inclusion criteria:&#xD;
&#xD;
             i. Surgery must have confirmed the recurrence. ii. A post-surgery MRI should be&#xD;
             available within 48 hours following surgery, and must show residual and measurable&#xD;
             disease.&#xD;
&#xD;
             iii. Craniotomy or intracranial biopsy site must be adequately healed free of drainage&#xD;
             or cellulitis, and the underlying cranioplasty must appear intact at the time of study&#xD;
             inclusion.&#xD;
&#xD;
          8. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          9. For orally administered drugs, the patient must be able to swallow and tolerate oral&#xD;
             medication and must have no known malabsorption syndrome.&#xD;
&#xD;
         10. Because of the risks of drug treatment to the developing foetus, women of&#xD;
             child-bearing potential and men must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) for the duration of study participation,&#xD;
             and for four months following completion of study therapy. Male patients should avoid&#xD;
             impregnating a female partner. Male patients, even if surgically sterilized, (i.e.&#xD;
             post-vasectomy) must agree to one of the following: practice effective barrier&#xD;
             contraception during the entire study treatment period and through 4 months after the&#xD;
             last dose of study drug, or completely abstain from sexual intercourse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing toxicity &gt; grade 2, other than alopecia.&#xD;
&#xD;
          2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or&#xD;
             hormonal other than for replacement) except for medications that are prescribed for&#xD;
             supportive care but may potentially have an anti-cancer effect (e.g., megestrol&#xD;
             acetate, bisphosphonates). These medications must have been started â‰¥ 1 week prior to&#xD;
             enrollment on this study.&#xD;
&#xD;
          3. Patient is pregnant or nursing.&#xD;
&#xD;
          4. Patients with known active progressive brain metastases. Patients with previously&#xD;
             treated brain metastases are eligible, provided that the patient has not experienced a&#xD;
             seizure or had a clinically significant change in neurological status within the 3&#xD;
             months prior to registration. All patients with previously treated brain metastases&#xD;
             must be stable for at least 1 month after completion of treatment and off steroid&#xD;
             treatment prior to study enrollment.&#xD;
&#xD;
             * Additional exclusion criteria specific for glioblastoma patients:&#xD;
&#xD;
               1. Patients who require anti-convulsant therapy must be taking non-enzyme inducing&#xD;
                  antiepileptic drugs (non-EIAED). EIAED are prohibited. Patients previously on&#xD;
                  EIAED must be switched to non-EIAED at least 2 weeks prior to randomization.&#xD;
&#xD;
               2. No radiotherapy within the three months prior to the diagnosis of progression.&#xD;
&#xD;
               3. No radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or&#xD;
                  brachytherapy unless the recurrence is histologically proven.&#xD;
&#xD;
          5. Patients with clinically significant preexisting cardiac conditions, including&#xD;
             uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or&#xD;
             symptomatic congestive heart failure are not eligible.&#xD;
&#xD;
          6. Patients with known left ventricular ejection fraction (LVEF) &lt; 40% are not eligible&#xD;
&#xD;
          7. Patients with stroke (including TIA) or acute myocardial infarction within 3 months&#xD;
             before the first dose of study treatment are not eligible&#xD;
&#xD;
          8. Patients with any other clinically significant medical condition which, in the opinion&#xD;
             of the treating physician, makes it undesirable for the patient to participate in the&#xD;
             study or which could jeopardize compliance with study requirements including, but not&#xD;
             limited to: ongoing or active infection, significant uncontrolled hypertension, or&#xD;
             severe psychiatric illness/social situations.&#xD;
&#xD;
        For each drug included in this protocol, specific inclusion and exclusion criteria (based&#xD;
        on the Package Insert or manufacturers recommendations) may also apply. These can be found&#xD;
        in the supplemental information about each agent included in the drug-specific study&#xD;
        manuals. Drug-specific inclusion and exclusion criteria will take precedence over the&#xD;
        inclusion/exclusion criteria listed above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E.E. Voest, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>E.E. Voest, prof.</last_name>
    <phone>0031205129111</phone>
    <email>DRUP@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>D.L. vd Velden, MD</last_name>
    <phone>0031205129111</phone>
    <email>DRUP@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meander Medical Center</name>
      <address>
        <city>Amersfoort</city>
        <state>Utrecht</state>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.J. Bloemendal, MD</last_name>
    </contact>
    <investigator>
      <last_name>G.A. Cirkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Noordwesr ziekenhuis Alkmaar (NWZ)</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.P. Hendriks, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>M.P. Hendriks, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekehuisgroep Twente</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siemerik</last_name>
    </contact>
    <investigator>
      <last_name>Siemerik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.E. Voest, prof.</last_name>
      <phone>0031205129111</phone>
      <email>DRUP@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>L. Zeverijn, MD</last_name>
      <phone>0031205129111</phone>
      <email>DRUP@nki.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Labots</last_name>
    </contact>
    <investigator>
      <last_name>M Labots</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriaan Bins, MD, PhD</last_name>
      <email>a.d.bins@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>A Bins, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis (OLVG)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.D. Kerver</last_name>
    </contact>
    <investigator>
      <last_name>E.D. Kerver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre ziekehuizen</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S.C.S. Tromp</last_name>
    </contact>
    <investigator>
      <last_name>S.C.S. Tromp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van Voorthuizen</last_name>
    </contact>
    <investigator>
      <last_name>van Voorthuizen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Westgeest, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>H. Westgeest, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reiner de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V.O. Dezentje</last_name>
    </contact>
    <investigator>
      <last_name>V.O. Dezentje</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haaglanden medisch centrum</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeurissen</last_name>
    </contact>
    <investigator>
      <last_name>Jeurissen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haga ziekehuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hautsma</last_name>
    </contact>
    <investigator>
      <last_name>Hautsma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imholz</last_name>
    </contact>
    <investigator>
      <last_name>Imholz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekehuis Nij Smellinghe</name>
      <address>
        <city>Drachten</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hovenga</last_name>
    </contact>
    <investigator>
      <last_name>Hovenga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekehuis Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>de Mol</last_name>
    </contact>
    <investigator>
      <last_name>dr Mol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G Vreugdenhil, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>G Vreugdenhil, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orbis Concern</name>
      <address>
        <city>Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F L Erdkamp, MD</last_name>
    </contact>
    <investigator>
      <last_name>F L Erdkamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rivas zorggroep</name>
      <address>
        <city>Gorinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.A. Davidis</last_name>
    </contact>
    <investigator>
      <last_name>M.A. Davidis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van Rooijen</last_name>
    </contact>
    <investigator>
      <last_name>van Rooijen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D.J.A. de Groot, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>D.J.A. de Groot, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.J. de Klerk</last_name>
    </contact>
    <investigator>
      <last_name>G.J. de Klerk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Treant zorggroep</name>
      <address>
        <city>Hoogeveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oldenhuis</last_name>
    </contact>
    <investigator>
      <last_name>Oldenhuis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwaarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>de Graaf</last_name>
    </contact>
    <investigator>
      <last_name>de Graaf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.J. Gelderblom, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>A.J. Gelderblom, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Hoeben, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>A. Hoeben, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius ziekhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Los</last_name>
    </contact>
    <investigator>
      <last_name>Los</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud umc</name>
      <address>
        <city>NIjmegen</city>
        <zip>6225GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C.M.L. van Herpen, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>H Verheul, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bravis</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boudewijn</last_name>
    </contact>
    <investigator>
      <last_name>Boudewijn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Fransicus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A P Hamberg, MD</last_name>
    </contact>
    <investigator>
      <last_name>A P Hamberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.J.A. de Jonge, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>M.J.A. de Jonge, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L.V. Beerepoot, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>L.V. Beerepoot, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.H.G. Langenberg, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>L Devriese, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Viecuri</name>
      <address>
        <city>Venray</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van der wouw</last_name>
    </contact>
    <investigator>
      <last_name>van der Wouw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>de Groot</last_name>
    </contact>
    <investigator>
      <last_name>de Groot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Molecular tumor profile</keyword>
  <keyword>Multidisciplinary tumor board</keyword>
  <keyword>Antitumor drugs</keyword>
  <keyword>Molecular Targeted Therapy</keyword>
  <keyword>Drug Repositioning</keyword>
  <keyword>Off-Label Use</keyword>
  <keyword>Sequence Analysis, DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
    <mesh_term>Afatinib</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
    <mesh_term>Rucaparib</mesh_term>
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

